Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 m...

Full description

Bibliographic Details
Main Authors: Mathilde Chanut, Rym Jaidi, Milena Kohn, Thomas Grange, Clara Brones, Naëlle Lombion, Philippe Rousselot, Thomas Longval
Format: Article
Language:English
Published: Taylor & Francis Group 2022-05-01
Series:Platelets
Subjects:
immune thrombocytopenic purpura
mrna sars cov2 vaccine
rechallenge
Online Access:http://dx.doi.org/10.1080/09537104.2022.2044463

Internet

http://dx.doi.org/10.1080/09537104.2022.2044463

Similar Items